Zhejiang Huahai Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is RIVAROXABAN USP, with a corresponding US DMF Number 28323.
Remarkably, this DMF maintains an Active status since its submission on June 05, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 27, 2014, and payment made on July 01, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II